In Laura Jensen’s first 90 days at GoodRx, she’s found herself spending quite a lot of time on what’s happening in Washington, DC. Jensen joined GoodRx in July as chief commercial officer after a long …
Sarepta shares slide as DMD treatment woes pile up
The ESSENCE trial of Sarepta’s Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.
Jennifer Doudna startup Azalea Therapeutics launches with $82M
Figuring out how to transport genetic medicines to the right parts of the body remains one of the great technical challenges constraining CRISPR’s potential. Now, one of the inventors of a gene editing tool has …
As pharma pour billions in US manufacturing, CDMOs see future opportunities
CDMO executives say they are unfazed about the wave of pharma companies boosting their internal manufacturing capacity as they onshore to the US, noting this could have upsides for third-party service providers in the future …
Swiss biotech CDR-Life returns to Boehringer Ingelheim to partner on autoimmune T cell engager
CDR-Life has inked a second licensing pact with Boehringer Ingelheim, as the Zurich-based startup will work with the German drug company in a ripe area of dealmaking. For 38 million Swiss francs (about $48 million) …
Blackstone to pay Merck $700M to fund development of antibody-drug conjugate
Blackstone Life Sciences will give a major financial boost to Merck’s development of an antibody-drug conjugate targeting TROP2, taking over some of the financial risk for an asset the drugmaker acquired through a 2022 partnership …
Pfizer reports revenue decline, boosts earnings guidance and trims pipeline
Even as Pfizer is embroiled in what has become pharma’s most dramatic M&A battle in years, it still has a business to run that has nothing to do with Metsera. The New …
South Korean biotech sets up California startup to advance ADCs
ABL Bio, a multi-partnered South Korean biotech, is backing a new Palo Alto, CA-based startup to carry forward two antibody-drug conjugates. NEOK Bio emerged on Tuesday with a $75 million Series A, with ABL Bio …
Post-Hoc Live: M&A, FDA, MFN and more — with our cousins at the FT
It’s been a heck of a week (and it’s only Tuesday). Today on Post-Hoc Live at 11 a.m. ET, I’ll be joined by my colleague at the Financial Times, Global Pharmaceutical Editor Hannah Kuchler. Next week, we’ll both be in London for the FT and Endpoints News Global Pharma and Biotech Summit, and we wanted […]
UCB bags FDA okay for first drug to treat rare disease TK2d
People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.